Circulating microparticles as predictor of thrombotic events in BCR/ABL negative myeloproliferative disorders

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

ASWAD Mohamed Hussam KISSOVÁ Jarmila ŘÍHOVÁ Lucie ZAVŘELOVÁ J. OVESNÁ Petra PENKA Miroslav

Year of publication 2016
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description The clinical course of BCR/ABL negative myeloproliferative disorders (MPNs) is frequently complicated by thrombotic events. Microparticles (MPs) are membrane fragments with diameter of 0.1 to 1 microm, which are released by most cell types during their activation or apoptosis. The level of microparticles is known to be elevated in thromboembolic diseases and malignancies. Objective: The aim of this work is to describe the contribution of platelet MPs level and their procoagulant activity to the occurrence of thrombotic complication in patients with BCR/ABL negative MPNs. Methods: The cohort of 121 patients with MPNs (73 males, 48 females) includes 76 patients with essential thrombocythemia, 25 polycythemia vera and 20 primary myelofibrosis. In this cohort was analysed the level of platelet MPs by using flowcytometry and procoagulation activity of MPs by using functional assay (Zymuphen MP-activity kit, Hyphen BioMed). The normal range was confirmed by examination of healthy individuals. Results: The level of platelet MPs was statistically significantly higher in patients with MPNs as compared with healthy individuals (p<0.001); the significancy was confirmed also for procoagulant activity of MPs (p<0.001). Evaluation of patients with history of thrombosis shown no statistically differences in comparison with patients without thrombosis; procoagulant activity of MPs was close to statistical significancy for patients with venous thrombosis (mean 13.7 nM; 95%CI 4.4-42.6 nM vs. 10.7; 95% CI 3.6-31.7 nM; p=0.095). JAK2V617F mutated patients have the higher level of platelet MPs (p=0.047), this correlation was not proven for procoagulant activity of MPs. The level of platelet MPs in patients with polycythemia vera was higher than other types of MPNs (p=0.002). Conclusion: The results of MPs examination might demonstrate the persistent prothrombotic state in patient with MPNs. The clinical utility of MP examination as marker of an increased risk of thrombosis has not been determined yet. The futher studies are needed.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.